Regulators have already started to denounce companies for misdirecting the public on the safety and efficacy of reference products compared to biosimilars, and it is important to continue to do so, said Kashyap Patel, MD , CEO of Carolina Blood and Cancer Care Associates.

Regulators have already started to denounce companies for misdirecting the public on the safety and efficacy of reference products compared to biosimilars, and it is important to continue to do so, said Kashyap Patel, MD , CEO of Carolina Blood and Cancer Care Associates.

Transcription

How important do you think the truthfulness of advertising is to ensuring a fair and competitive market for organic products, and do you think the original companies play fairly?

So I’m not really in the know to dissect the legal part of it, but I think transparency is the foundation of delivering better health care. And I realized that I think a few companies were actually, I would say 5, criticized by the FDA or some other authority, I can’t remember which authority actually. But someone from the regulatory agency kind of called them out for that kind of information, which would deter patients or beneficiaries from opting for biosimilars. They have been used for almost 15 years around the world. If you look in Europe, I think at the last count there were around 100 million unique doses of biosimilars being used between different parts of the world. And I don’t think there has been a significant safety issue that is highlighted by a flashing red light. So I have sort of reservations against practices that misdirect patient populations and I think the industry should stay within their ethical and moral guidelines, rather than trying to see how to increase sales. I think Onpro has its own rules. I mean, don’t get me wrong. I asked my patients if they feel comfortable, if they have enough money to pay the out-of-pocket expenses, if they want to. We give them the opportunity to discuss the product with them and I think our patient population in rural South Carolina has been more comfortable with the traditional use of cheaper alternatives rather than opting for a more expensive alternative.